[Research Advance of CXCR4 Inhibitors in the Treatment of Acute Myeloid Leukemia--Review].

Liang, Jing-Ping; Li, Wei

Liang, Jing-Ping; Li, Wei.

Afiliación

Liang JP; Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Li W; Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China,E-mail: liwei160@yahoo.com.

Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 29(4): 1355-1359, 2021 Aug.

Article en Zh | MEDLINE | ID: mdl-34362530

RESUMEN

CXCL12/CXCR4 axis composed of chemokine CXCL12 and its specific ligand CXCR4 can regulate and control the adhesion of leukemia cells to protective bone marrow niche, promote cell survival, and resist apoptosis induced by signal transduction inhibitors and chemotherapeutic drugs. Therefore, CXCL12 /CXCR4 axis has become a new target for the treatment of acute myeloid leukemia. At present, CXCR4 inhibitors that have been developed are in different clinical trials, showing good anti-leukemia effect. In this review, the research advance of CXCR4 inhibitors in the treatment of acute myeloid leukemia is summarized briefly.

Asunto(s)

Antineoplásicos; Leucemia Mieloide Aguda; Antineoplásicos/uso terapéutico; Apoptosis; Médula Ósea; Quimiocina CXCL12/farmacología; Humanos; Leucemia Mieloide Aguda/tratamiento farmacológico; Receptores CXCR4; Transducción de Señal

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Antineoplásicos Límite: Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google